Evidence map›Paper›PMID 42734108›Full record

ArticleCancer medicine2026

Cancer Patients Mortality From Other Causes: A European Population-Based Study.

Gemma Gatta, Riccardo Capocaccia, Silvia Rossi, Maria Athanasiadou, Damien Bennett, Ladislav Dusek, Jaume Galceran, Monica Hackl, Bernd Holleczek, Kaire Innos and 13 more

Abstract read
In one paragraph

Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Gemma GattaUniversità Milano Bicocca, Milan, Italy.ORCID https://orcid.org/0000-0003-4160-6458
Riccardo CapocacciaEditorial Board, Epidemiologia e Prevenzione, Milan, Italy.ORCID https://orcid.org/0000-0002-1455-1992
Silvia RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID https://orcid.org/0000-0002-9815-2904
Maria AthanasiadouCyprus Ministry of Health, Nicosia, Cyprus.
Damien BennettNorthern Ireland Cancer Registry, Queen's University Belfast, Belfast, UK.ORCID https://orcid.org/0000-0003-2053-7078
Ladislav DusekBiostatistics and Analysis Institute, Masarykova University, Brno, Czech Republic.ORCID https://orcid.org/0000-0002-8589-4378
Jaume GalceranEpidemiology and Prevention Cancer Service, Hospital Universitari Sant Joan de Reus, IISPV, Reus, Spain.ORCID https://orcid.org/0000-0002-1584-7293
Monica HacklAustrian National Cancer Registry, Wien, Austria.
Bernd HolleczekSaarland Cancer Registry, Saarbrücken, Germany.ORCID https://orcid.org/0000-0001-8759-4371
Kaire InnosNational Institute for Health Development, Tallin, Estonia.ORCID https://orcid.org/0000-0003-0120-2213
Alexander KatalinicInstitute of Social Medicine and Epidemiology, University of Lubeck, Lübeck, Germany.ORCID https://orcid.org/0000-0003-0490-1554
Raphael Marcos-GrageraGirona Cancer Registry, Catalan Institute of Oncology, Girona, Spain.ORCID https://orcid.org/0000-0001-9824-3657
Deirdre MurrayNational Cancer Registry Ireland and Department of Public Health, University College Cork, Cork, Ireland.ORCID https://orcid.org/0009-0006-3868-4737
Robin SchaffarGeneva Cancer Registry, Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-4023-8756
Stephanie SmitsWelsh Cancer Intelligence and Surveillance Unit, Public Health Wales, Cardiff, UK.ORCID https://orcid.org/0000-0001-7897-150X
Giedrė SmailytėLithuania National CR, Institute of Oncology, Vilnius University, Vilnius, Lithuania.ORCID https://orcid.org/0000-0001-8365-543X
Hans StormDanish Cancer Society, Copenhagen, Denmark.ORCID https://orcid.org/0000-0001-7223-8198
Claudia VenerEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.ORCID https://orcid.org/0000-0001-7351-8634
Tina ŽagarSlovenian Cancer Registry, Institute of Oncology Ljubljana, Ljubljana, Slovenia.ORCID https://orcid.org/0000-0002-0532-1351
Alice BernasconiEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.ORCID https://orcid.org/0000-0001-8522-6882
Valerie JoosteDigestive Cancer Registry of Burgundy Dijon, Dijon, France.ORCID https://orcid.org/0000-0002-9902-0700
Laura BottaEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.ORCID https://orcid.org/0000-0002-2793-5338
EUROCARE‐6 WG

Funding

Estonian Research Competency Council PRG2543
6 · The paper itself

Abstract

introductionCancer patients may face elevated mortality not only from their malignancy but also from other factors including multi-morbidity and the impact of treatment-related complications. This study analyses mortality from all causes other than the index cancer among cancer patients compared to the general population.

methodsWe analysed EUROCARE-6 data on 1,894,057 cancers diagnosed in 13 European countries and collected by 17 cancer registries with complete official cause-of-death information. Included were first-primary head and neck (H&N), stomach, colorectal, lung, breast, cervical, endometrial, ovarian, prostatic, kidney, and bladder cancers diagnosed between 1998 and 2013 in patients aged 15-79, with follow-up until 31st December 2014. We estimated the relative risk (RR) of death from all other causes for patients relative to population mortality rates. Cause-specific survival (CSS) was compared to relative survival (RS) at 5 and 10 years.

resultsRR were > 2 for H&N and female lung cancers, between 1 and 2 for stomach, male lung, cervix, endometrial, ovary, kidney and bladder, and < 1 for prostate and female breast cancers. Relative risk declined with increasing age for almost all cancer types. Ten-year CSS exceeded RS by 7%-11% points (pp) in H&N cancers, with smaller differences in bladder (2-6 pp), stomach, lung, cervix, ovary and kidney (2-3 pp). CSS was lower than RS in breast and prostate cancers.

conclusionDifferentiation between deaths due to the index cancer and to all other causes is crucial for patient follow-up and to improve quality of life. Cause-of-death data should be a core component of population-based cancer registries to inform interpretation of survivorship data.

Indexed as

NeoplasmsAdolescentAdultAgedCause of DeathEuropeFemaleHumansMaleMiddle AgedRegistriesYoung Adult

Identifiers

PMID42734108
PMCPMC13573084

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.